Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|180|2|224-235

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.2, 2018-01, pp. : 224-235

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 4, 2015-08 ,pp. : 496-503

John Wiley & Sons Inc

Access to resources Recommend Favorite

Activity of Thalidomide and Lenalidomide in Mantle Cell Lymphoma

By  

Acta Haematologica, Vol. 123, Iss. 1, 2009-11 ,pp. : 21-29

Karger

Access to resources Recommend Favorite

A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 4, 2015-05 ,pp. : 528-533

John Wiley & Sons Inc

Access to resources Recommend Favorite

Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 557-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 132-138

John Wiley & Sons Inc

Access to resources Recommend Favorite